An old women, nanda suffered stroke for which she was given alteplase. She improved considerably. To prevent the recurrence of stroke, this patient is most likely to be treated indefinitely with:
First, I need to recall what alteplase is used for. Alteplase is a thrombolytic agent, right? So it's given for acute ischemic stroke to dissolve the clot. But after that, to prevent another stroke, the patient would need ongoing therapy.
The key here is to think about secondary prevention strategies for stroke. For ischemic stroke, the main goals are to prevent clot formation again. The main options here would be anticoagulants or antiplatelets. Common drugs for this are aspirin, clopidogrel, maybe warfarin, or newer anticoagulants like DOACs. But the question says "most likely to be treated indefinitely."
Wait, let's think about the options. If the stroke was due to atrial fibrillation, then anticoagulants like warfarin or DOACs would be needed. But if it's a different cause, like atherosclerosis, then antiplatelets like aspirin are standard. Since the question doesn't specify the cause, but asks for the most likely treatment, I think the answer is aspirin. Because in the absence of a known cardiac source (like AFib), antiplatelets are first-line for secondary prevention.
Looking at the options (even though the options aren't listed here), the common choices would be aspirin, clopidogrel, warfarin, or maybe heparin. But heparin is not used long-term. So the likely correct answer is aspirin. The other options: clopidogrel might be an alternative, but aspirin is more standard. Warfarin is for AFib, which isn't mentioned. So the answer is aspirin.
**Core Concept**
This question tests knowledge of **secondary stroke prevention strategies** in ischemic stroke. The focus is on **antiplatelet therapy** versus **anticoagulation**, depending on stroke etiology. Alteplase (tPA) is used for acute reperfusion, but long-term prevention requires addressing underlying risk factors like atherosclerosis or hypercoagulability.
**Why the Correct Answer is Right**
The correct answer is **aspirin**. After an ischemic stroke of **atherothrombotic origin** (most common cause in elderly patients without AF), **aspirin** is the first-line antiplatelet agent for indefinite secondary prevention. It irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, reducing thromboxane A2 production and platelet aggregation. This lowers the risk of recurrent stroke by ~20–30% in clinical trials like ESPS-2.
**Why Each Wrong Option is Incorrect**
**Option B: Warfarin** is incorrect unless the stroke was caused by **atrial fibrillation** (not mentioned in the question). Warfarin is an anticoagulant, not antiplatelet, and requires regular INR monitoring.
**Option C: Clopidogrel** is a P2Y12 inhibitor and an alternative to aspirin, but **aspirin** is the standard first-line agent unless